Tranexamic Acid Underused in Surgery Despite Strong Evidence It Saves Lives
A new NEJM editorial calls for broader surgical adoption of tranexamic acid, a proven blood-loss-reducing drug that remains underutilized worldwide.
Summary
Tranexamic acid (TXA) is a well-established, inexpensive drug that reduces surgical bleeding and saves lives — yet it remains significantly underused in operating rooms globally. This editorial in the New England Journal of Medicine, tied to the TRACTION initiative, argues that closing the gap between evidence and practice is an urgent patient safety priority. Surgical bleeding contributes to millions of preventable deaths and complications each year, and TXA has been shown in large trials to cut mortality when given promptly. Despite this, adoption in elective and emergency surgery is inconsistent. The authors, affiliated with Oxford and the London School of Hygiene and Tropical Medicine, use this platform to advocate for systemic changes in surgical protocols to make TXA standard of care rather than an exception.
Detailed Summary
Surgical bleeding remains one of the most preventable causes of death and serious complications in both emergency and elective procedures. Tranexamic acid (TXA), an antifibrinolytic drug that prevents blood clot breakdown, has accumulated robust evidence across major trials showing it significantly reduces blood loss, transfusion requirements, and mortality. Yet despite this evidence base, its routine surgical use lags far behind what the data supports.
This editorial by Murphy and Roberts, published in the New England Journal of Medicine in June 2026, accompanies the TRACTION trial and makes a forceful case for dramatically expanding TXA use across surgical settings. TRACTION appears designed to investigate strategies that increase TXA uptake in real-world surgical practice, addressing the persistent evidence-to-practice gap that costs lives.
The authors represent leading institutions in transfusion medicine and clinical trials — NHS Blood and Transplant, Oxford University Hospitals, and the London School of Hygiene and Tropical Medicine — lending significant authority to their call to action. Their framing suggests that the problem is no longer scientific uncertainty but rather institutional inertia and implementation failure.
For clinicians, the implications are direct: TXA is safe, cheap, and effective, and withholding it from surgical patients represents an avoidable harm. The editorial likely reviews barriers to adoption and proposes concrete solutions, potentially including protocol standardization, provider education, and system-level mandates.
Caveats include that this is an editorial, not primary data, and the full text is unavailable for detailed review. The precise findings of the TRACTION trial itself are not summarized here. Nonetheless, the message aligns with a growing global consensus: tranexamic acid should be a universal surgical standard, and the gap between evidence and practice must be closed urgently.
Key Findings
- Tranexamic acid remains widely underused in surgery despite strong trial evidence it reduces death and blood loss.
- The TRACTION initiative targets the evidence-to-practice gap in surgical TXA adoption.
- TXA is inexpensive and has a well-established safety profile, making non-use difficult to justify.
- Institutional inertia, not lack of evidence, is identified as the primary barrier to broader surgical use.
- Authors from Oxford and LSHTM call for systemic protocol changes to make TXA standard surgical care.
Methodology
This is an editorial commentary published in the New England Journal of Medicine accompanying the TRACTION trial. It does not present original primary data but synthesizes existing evidence and contextualizes the TRACTION trial findings. Methodology of the underlying trial cannot be fully assessed from the abstract alone.
Study Limitations
This summary is based on the abstract and editorial metadata only, as the full text is not open access. The specific findings and design of the TRACTION trial cannot be fully evaluated. As an editorial rather than a primary research paper, it reflects expert opinion and synthesis rather than new empirical data.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.